刘兆国

师资介绍

刘兆国，男，汉族，1987年11月生，博士，副教授，硕士生导师。

教育经历：

2007.09-2011.06盐城工学院，生物工程，学士

2011.09-2016.06南京中医药大学，中药药理学，博士

工作经历：

2016.07-2016.10 香港浸会大学，博士后

2016.11-2019.06南通大学，药学院，讲师

2019.07-至今 南通大学，药学院，副教授

研究方向：

中药药理学（中药复方及其活性成分抗结肠炎/癌及肝纤维化的效应与机制研究）

社会学术兼职：

江苏省药理学会临床前药理专委会委员；江苏省药理学会中药药理委员会委员；江苏省双创人才（科技副总）

基金项目：

1. 国家自然科学基金面上项目，82374228，乌梅丸通过AHCY蛋白介导RIG-I乳酸化修饰调控巨噬细胞极化抗CAC的作用及机制研究，2024/01-2027/12，49万元，在研，主持

2. 国家自然科学基金青年项目，81703884，基于PKCδ介导的自噬调控探究黄葵胶囊对顺铂肾毒性的保护作用及分子机制，2018/01-2020/12，20万元，已结题，主持

3. 中国博士后科学基金面上项目，2018M642296，黄葵胶囊抗顺铂所致肾毒性的机理研究，2018/11-2020/08，5万元，已结题，主持

4. 南通市科技计划项目，JC2021025，基于 MIF/MIOX/铁死亡信号调控探究黄葵胶囊抗顺铂急性肾损伤的机制研究，2021/07-2023/06，5万元，已结题，主持

5. 江苏省高等学校自然科学研究面上项目，17KJB360012，黄葵胶囊对顺铂肾毒性的保护作用及机理研究，2017/09-2019/08，3万元，已结题，主持

科研成果：

近5年侧重于中药复方及其活性成分抗结肠相关疾病（结肠炎、结肠癌）及肝纤维化的效应及机制研究。课题组主要运用细胞模型、整体动物模型结合分子生物学、蛋白质组学、网络药理学及生信分析技术，着力挖掘潜在的抗结肠癌及抗肝纤维化中药复方及中药活性成分，并揭示其发挥作用的机理，为临床研究提供重要实验依据。

研究工作受到国家自然科学基金委员会、中国博士后科学基金会及南通市科技局各类基金项目支持，包括1项国家自然科学基金青年基金项目、1项国家自然科学基金面上项目、1项中国博士后科学基金面上项目、1项南通市科技计划项目支持，取得了一系列具有一定科学价值的研究成果。

在Oxidative Medicine and Cellular Longevity、Journal of Cellular and Molecular Medicine、International Immunopharmacology、International Journal of Molecular Sciences、Biomedicine & Pharmacotherapy及Frontiers in Pharmacology等期刊发表专业学术论文20余篇，其中中科院二区论文15篇，论文累积被引700余次。

成果奖励：

1、南通市首届十佳中药年度人物（2022）

2、南通大学第十二届青年教师讲课竞赛一等奖（2021）

3、南通大学优秀教育工作者（2021）

代表性论文：

1. Weiling Lin^#, Bangjie Gu^#, Yuayuan Gu^#, Rui Zhao, Yumeng Huang, Rui Fan, Weihao Rong^*,Zhaoguo Liu^*. Taraxasterol protects against acetaminophen-induced hepatotoxicity by reducing liver inflammatory response and ameliorating oxidative stress in mice [J].International Immunopharmacology, 2024, 138: 112580.

2. Zirong Deng^#, Yun Xu^#, Yuchen Cai, Weiling Lin, Libei Zhang, Aoqing Jiang, Yuhang Zhou, Rui Zhao, Heyan Zhao,Zhaoguo Liu^* and Tingdong Yan^*. Inhibition of ribosomal RNA Processing 15 homolog (RRP15) suppressed tumor growth, invasion and epithelial to mesen-chymal transition (EMT) of colon cancer [J].International Journal of Molecular Sciences, 2023, 24(4): 3528.

3. Libei Zhang^#, Weiling Lin^#, Yunqing Cai^#, Ziyou Huang, Rui Zhao, Tingdong Yan, HongtaoXu^*,Zhaoguo Liu^*. Farnesoid X receptor activation is required for the anti-inflammatory and anti-oxidative stress effects of Alisol B 23-acetate in carbon tetrachloride-induced liver fibrosis in mice [J].International Immunopharmacology, 2023, 123:110768.

4. Jue Wang^#, Kang Ding^#, Yuhang Wang^#, Tingdong Yan, Yun Xu, Zirong Deng, Weiling Lin, Libei Zhang, Weizhong Zhu, Rui Zhao, Yuhang Zhou,Zhaoguo Liu^*. Wumei Pill ameliorates AOM/DSS-induced colitis-associated colon cancer through inhibition of inflammation and oxidative stress by regulating S-adenosylhomocysteine hydrolase- (AHCY-) mediated hedgehog signaling in mice [J].Oxidative Medicine and Cellular Longevity, 2022, 2022:4061713.

5.Zhaoguo Liu^#, Mengjue Tu^#, Jiannan Shi^#, Hong Zhou, Guoliang Meng, Jianguo Gu^*, Yuqin Wang^*. Inhibition of fucosylation by 2-fluorofucose attenuated acetaminophen-induced liver injury via its anti-inflammation and anti-oxidative stress effects [J].Frontiers in Pharmacology, 2022, 13:939317.

6. Chang Chen^#, Jingya Gu^#, Jue Wang^#, Yu Wu, Aihua yang, Tingting Chen, Tingting Zhou,Zhaoguo Liu^*. Physcion 8-O-β-glucopyranoside ameliorates liver fibrosis through inflammation inhibition by regulating SIRT3-mediated NF-κB P65 nuclear expression [J].International Immunopharmacology, 2021, 90: 107206.

7. Yuqin Wang^#, Chunling Li^#, Jingya Gu^#, Chang Chen, Jiaxin Duanmu, Jing Miao, Wenjuan Yao, Jinhua Tao, Mengjue Tu, Biao Xiong, Lingling Zhao^*,Zhaoguo Liu^*. Celastrol exerts anti-inflammatory effect in liver fibrosis via activation of AMPK-SIRT3 signaling [J].Journal of Cellular and Molecular Medicine, 2020, 24 (1): 941-953.

8. Jingya Gu^#, Chang Chen^#, Jue Wang^#, Tingting Chen, Wenjuan Yao, Tingdong Yan^*,Zhaoguo Liu^*. Withaferin A exerts preventive effect on liver fibrosis through oxidative stress inhibition in a sirtuin 3-dependent manner [J].Oxidative Medicine and Cellular Longevity, 2020, 2020: 2452848.

9. Jinlin Zhang, Aihua Yang, Yu Wu, Wei Guan, Biao Xiong, Xiaoqing Peng, Xiaojin Wei, Chang Chen,Zhaoguo Liu^*. Stachydrine ameliorates carbon tetrachloride- induced hepatic fibrosis by inhibiting inflammation, oxidative stress and regulating MMPs/TIMPs system in rats [J].Biomedicine & Pharmacotherapy, 2018, 97: 1586-1594.

10.Zhaoguo Liu^#,*, Pingting Zhu^#, Lin Zhang, Biao Xiong, Jinhua Tao, Wei Guan, Chunling Li, Chang Chen, Jingya Gu, Jiaxin Duanmu, Wei Zhang^*. Autophagy inhibition attenuates the induction of anti-inflammatory effect of catalpol in liver fibrosis [J].Biomedicine & Pharmacotherapy, 2018, 103:1262-1271.

11. Lin Zhang^#, Chang Chen^#, Jiaxin Duanmu, Yan Wu, Jinhua Tao, Aihua Yang, Xiaoqin Yin, Biao Xiong, Jingya Gu, Chunling Li,Zhaoguo Liu^*. Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF-1α nuclear translocation [J].International Immunopharmacology, 2018, 65: 429-437.

12. Pingting Zhu^#, Yu Wu^#, Aihua Yang, Xingsheng Fu, Ming Mao,Zhaoguo Liu^*. Catalpol suppressed proliferation, growth and invasion of CT26 colon cancer by inhibiting inflammation and tumor angiogenesis [J].Biomedicine & Pharmacotherapy, 2017, 95:68-76.